Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions (Favipiravir)

Open-label, Randomised, Single Oral Dose, Two-period, Cross-over Trial to Assess to Bioequivalence of Favira 200 mg FT in Comparison With Avigan 200 mg FT in Healthy Male Subjects Under Fasting Conditions

A single dose of Reference product containing 200 mg favipiravir and a single dose of Test product containing 200 mg favipiravir or vice versa; administered with 240 mL of water at room temperature, in each period under fasting conditions with current pandemic precautions.

Study Overview

• Status: Completed
• Conditions: Bioequivalence
• Intervention / Treatment: Drug: FAVIRA 200 MG Film Tablet; Drug: AVIGAN 200 MG Film Tablets

Detailed Description

Favipiravir is a drug with a mechanism of action different from that of the existing influenza antiviral drugs and effective against all types and sub-types of human influenza A, B and C viruses in vitro, showing anti-viral activity against various influenza virus strains including avian and swine viruses. Favipiravir also has shown anti-viral activity even against amantadine, oseltamivir and zanamivir-resistant influenza viruses in vitro. The mechanism of action of favipiravir is the selective inhibition of RNA polymerase by favipiravir ribosyl triphosphate formed by cellular enzymes in the influenza virus leading to antiviral activity.

• Study Type: Interventional
• Enrollment (Actual): 30
• Phase: Phase 1

Contacts and Locations

Study Locations

• Turkey
  • Ankara
    • Akyurt, Ankara, Turkey, 06970
      • Novagenix Drug R&D Center
  • Gaziantep
    • Sahinbey, Gaziantep, Turkey, 27000
      • Farmagen Ar-Ge Biyot. Ltd. Sti.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years to 40 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

1. Healthy Caucasian male subjects aged between 20 and 40 years,
2. Non smokers or smoking maximum 5 cigarettes a day, those who won't smoke or drink coffee during the study period,
3. Two Negative Covid-19 PCR test results.
4. Negative alcohol breath test results,
5. Normal physical examination at screening visit,
6. Having the Body Mass Index ranged between 18.5-30 kg/m2 (see Appendix I) which is in the desirable range according to the age,
7. Ability to communicate adequately with the investigator himself or his representatives,
8. Ability and agreement to comply with the study requirements,
9. Normal blood pressure and heart rate measured under stabilised conditions at the screening visit after at least 5 minutes of rest under supine position: SBP within 100 to 140 mmHg, DBP within 60 to 90 mmHg and HR within 50 to 90 bpm,
10. Normal/ acceptable 12-lead electrocardiographic results at least after 5 minutes of rest,
11. Laboratory results within normal range or clinically non-significant (CBC, glucose, urea, uric acid, creatinine, estimated GFR (eGFR), total bilirubin, sodium, potassium, calcium, chloride, SGOT (AST), SGPT (ALT), GGT, alkaline phosphatase, total protein and urinalysis), drug addiction scanning in urine results in negative (amphetamine, barbiturate, benzodiazepine, cannabinoid, cocaine, opiate),
12. Understanding of the study and agreement to give a written informed consent according to section 20.3.
13. Understanding of that he and his partner will use a practice adequate contraception during the study and at least 7 days after the study.
14. Volunteer's compliance with isolation rules defined at study protocol.

Exclusion Criteria:

1. Who have atopic constitution or asthma or known allergy for favipiravir and/or any other ingredients of the products.
2. Who have positive Covid-19 PCR test result.
3. Any history or presence of clinical relevance of cardiovascular, neurological, musculoskeletal, haematological, hepatic, gastrointestinal, renal, pulmonary, endocrinological, metabolism or psychiatric disease, any type of porphyria.
4. Symptomatic or asymptomatic orthostatic hypotension at screening or before the first drug administration defined by a decrease of SBP more than 20 mmHg or DBD more than 10 mmHg occurs between sitting/supine to standing position subject will be excluded (if it deemed necessary by the investigator),
5. Presence or history of malabsorption or any gastrointestinal surgery except appendectomy or except herniotomy.
6. Subjects who have given more than 400 mL blood within the last two months before the first drug administration and subjects who have participated to any drug research within the last two months before the first drug administration.
7. Subjects suspected to have a high probability of non-compliance to the study procedure and/or completion of the study according to the investigator's judgement.
8. Subjects who used any of prescribed systemic or topical medication (including OTC medication) within 2 weeks (or six elimination half lives of this medication, whichever is longer) before the initiation of the study (except single doses of analgesics which have no drug interaction with study product).
9. Use of any vitamins or herbal products within 7 days prior to the initial dose of the study medication.
10. History of allergic response to heparin.
11. Subjects who have any chronic disease which might interfere with absorption, distribution, metabolism or excretion of the drug.
12. Subjects who regular consumed of beverages or food containing methylxanthines (e.g. coffee, tea, cola, caffeine, chocolate, sodas,) equivalent to more than 500 mg methylxanthines per day.
13. Subjects who has taken any grapefruit or grapefruit juice during 7 days prior to drug administration, during the study.
14. History of drug abuse.
15. History of alcohol abuse and/or regular use of more than 2 units of alcohol per day or 10 units per week and/or positive alcohol breath test results (Note: one unit of alcohol equals 250 mL beer, 125 mL wine or 25 mL spirits).
16. Positive blood test for HBV, HCV and HIV.
17. Who have relationship to the investigator.
18. Who are not suitable to any of inclusion criteria.
19. History of difficulty of swallowing.
20. Intake of depot injectable solutions (including study medications) within 6 months before start of the study.
21. Intake of enzyme-inducing, organotoxic or long half-life drugs within 4 weeks before start of the study.
22. Special diet due to any reason, e.g. vegetarian.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: FAVIRA then AVIGAN; Participants first received Favira 200 mg FT manufactured by Novelfarma in a fasting state. After a washout period of 48 hours, they then received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./ Japan in a fasting state.	Drug: FAVIRA 200 MG Film Tablet; FAVIRA is containing 200 mg favipiravir manufactured by Novelfarma, Turkey.; Other Names: FAVIRA 200 MG FT; Drug: AVIGAN 200 MG Film Tablets; AVIGAN is containing 200 mg favipiravir manufactured by Toyama, Japan; Other Names: AVIGAN 200 mg FT
Experimental: AVIGAN then FAVIRA; Participants first received Avigan FT 200 mg manufactured by Toyama Chemical Industry Co.Ltd./Japan in a fasting state. After a washout period of 48 hours, they then received Favira 200 mg FT manufactured by Novelfarma in a fasting state.	Drug: FAVIRA 200 MG Film Tablet; FAVIRA is containing 200 mg favipiravir manufactured by Novelfarma, Turkey.; Other Names: FAVIRA 200 MG FT; Drug: AVIGAN 200 MG Film Tablets; AVIGAN is containing 200 mg favipiravir manufactured by Toyama, Japan; Other Names: AVIGAN 200 mg FT

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
AUC0-tlast	AUC0-tlast of favipiravir will be obtained from plasma concentrations	0 to 24 hours post dose
Favipiravir Cmax	Favipiravir Cmax Cmax of favipiravir will be obtained from plasma concentrations	0 to 24 hours post dose

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
AUC0-inf of Favipiravir	AUC0-inf of favipiravir will be obtained from plasma concentrations	0 to 24 hours post dose
Tmax of Favipiravir	tmax of favipiravir will be obtained from plasma concentrations	0 to 24 hours post dose

Collaborators and Investigators

• Sponsor: Novelfarma Ilaç San. ve Tic. Ltd. Sti.
• Collaborators: Novagenix Bioanalytical Drug R&D Center; Farmagen Ar-Ge Biyot. Ltd. Sti
• Investigators: Principal Investigator: Muradiye Nacak, MD,PhD, Farmagen Ar-Ge Biyot. Ltd. Sti; Study Chair: Taner Ezgi, MD, Farmagen Ar-Ge Biyot. Ltd. Sti

Study record dates

Study Major Dates

• Study Start (Actual): May 28, 2020
• Primary Completion (Actual): June 5, 2020
• Study Completion (Actual): June 18, 2020

Study Registration Dates

• First Submitted: May 19, 2020
• First Submitted That Met QC Criteria: May 19, 2020
• First Posted (Actual): May 22, 2020

Study Record Updates

• Last Update Posted (Actual): August 11, 2020
• Last Update Submitted That Met QC Criteria: August 7, 2020
• Last Verified: August 1, 2020

More Information

Terms related to this study

• Keywords: Antiviral Agents; Favipiravir; COVID-19 drug treatment; Novagenix; Farmagen
• Additional Relevant MeSH Terms: Anti-Infective Agents; Antiviral Agents; Favipiravir
• Other Study ID Numbers: NOV2020/1923; FARGE 367 (Other Identifier: FARMAGEN)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No